EI
RXRX icon

EFG International’s Recursion Pharmaceuticals RXRX Stock Holding History

EFG International’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,500
Closed -$4.61K – 1127
2026
Q1 		$4.61K Hold
1,500
– – ﹤0.01% 972
2025
Q4 		$6.13K Buy
+1,500
New +$7.43K ﹤0.01% 823

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EFG International's RXRX Position: Q2 2026 in Review

EFG International sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 1,500 shares — an estimated $4.61K sold.

EFG International first reported a position in RXRX in Q4 2025 and held it in 2 quarters. The position peaked at $6.13K in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • EFG International reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • EFG International sold 1,500 Recursion Pharmaceuticals shares in Q2 2026, an estimated $4.61K.
  • EFG International first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • EFG International's Recursion Pharmaceuticals position peaked at $6.13K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.